Lupin Share Price in Focus; Licenses Two Oncology Programmes to Kaveri Therapeutics

Lupin Inc. U.S.A., a wholly owned subsidiary of Lupin Limited, has entered into a licensing agreement with Kaveri Therapeutics, Inc. for 2 of its oncology programmes, as per the exchange filings. 

Under the transaction, Lupin has granted an exclusive perpetual licence for LNP7457 (PRMT5) and LNP8701 (SOS1) in exchange for an 82.2% equity stake in the U.S.-based clinical-stage oncology company. The transaction was completed on 20 July 2026.   

Oncology Assets Move into Global Clinical Development 

As part of the agreement, the two oncology programmes, valued at $1.6 million, have been transferred to Kaveri through an exclusive perpetual licence. 

In return, Lupin received 332,000 common shares, representing 82.2% ownership in Kaveri, and will also provide seed funding.  

Kaveri will advance both programmes through global clinical trials while raising additional capital to support their worldwide clinical development.   

Focus on Hard-to-Treat Cancers 

Kaveri's development programme will target PRMT5 and SOS1/RAS pathway biology, with an initial focus on solid tumours, including lung, pancreatic, ovarian and CNS-related cancers. 

The company will operate independently under Chief Executive Officer Kristi Jones and Chief Medical Officer Dr. Robert Pierce. Lupin said LNP7457 (PRMT5) and LNP8701 (SOS1) have already reported positive clinical data at the ASCO 2025 and ASCO 2026 meetings, respectively.  

Management Commentary 

Vinita Gupta, Chief Executive Officer of Lupin, said the company is "proud to have pioneered these oncology assets" and believes Kaveri's experienced leadership team is well positioned to accelerate the development of targeted oncology therapies. 

She added that the collaboration aims to bring "meaningful innovation to patients" by advancing the programmes through the next stages of clinical development.  

Read More: Emcure Pharmaceuticals Expands Poviztra Use for MASH Following CDSCO Approval! 

Lupin Share Price Performance  

As of 21 July 2026, at 11:41 AM, Lupin Ltd share price was trading at ₹2,502.50 per share, reflecting a surge of 0.97% from the previous trading session. 

Conclusion 

The agreement establishes Kaveri Therapeutics as the dedicated developer of Lupin's two oncology programmes while giving Lupin a majority equity stake in the company. The transaction aligns scientific development, funding and clinical execution to advance the therapies through global clinical studies.   

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.